These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 36463214)

  • 1. Participant perceptions on the acceptability and feasibility of a telemedicine-based HIV PrEP and buprenorphine/naloxone program embedded within syringe services programs: a qualitative descriptive evaluation.
    Corneli A; Perry B; Des Marais A; Choi Y; Chen H; Lilly R; Ayers D; Bennett J; Kestner L; Meade CS; Sachdeva N; McKellar MS
    Harm Reduct J; 2022 Dec; 19(1):132. PubMed ID: 36463214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Providing medication for opioid use disorder and HIV pre-exposure prophylaxis at syringe services programs via telemedicine: a pilot study.
    McKellar MS; Des Marais AC; Chen H; Choi Y; Lilly R; Ayers D; Bennett J; Kestner L; Perry B; Poley S; Corneli A; Meade CS; Sachdeva N
    Harm Reduct J; 2024 Mar; 21(1):69. PubMed ID: 38532395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. "We want everything in a one-stop shop": acceptability and feasibility of PrEP and buprenorphine implementation with mobile syringe services for Black people who inject drugs.
    Bartholomew TS; Andraka-Cristou B; Totaram RK; Harris S; Doblecki-Lewis S; Ostrer L; Serota DP; Forrest DW; Chueng TA; Suarez E; Tookes HE
    Harm Reduct J; 2022 Dec; 19(1):133. PubMed ID: 36463183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "Take services to the people": strategies to optimize uptake of PrEP and harm reduction services among people who inject drugs in Uganda.
    Kamusiime B; Beima-Sofie K; Chhun N; Nalumansi A; Nalukwago GK; Kasiita V; Twesige CC; Kansiime R; Muwonge TR; Kyambadde P; Kadama H; Mudiope P; Glick S; Lambdin B; Mujugira A; Heffron R
    Addict Sci Clin Pract; 2024 Feb; 19(1):13. PubMed ID: 38395940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Understanding the public health consequences of suspending a rural syringe services program: a qualitative study of the experiences of people who inject drugs.
    Allen ST; Grieb SM; O'Rourke A; Yoder R; Planchet E; White RH; Sherman SG
    Harm Reduct J; 2019 May; 16(1):33. PubMed ID: 31109339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Project CHARIOT: study protocol for a hybrid type 1 effectiveness-implementation study of comprehensive tele-harm reduction for engagement of people who inject drugs in HIV prevention services.
    Bartholomew TS; Plesons M; Serota DP; Alonso E; Metsch LR; Feaster DJ; Ucha J; Suarez E; Forrest DW; Chueng TA; Ciraldo K; Brooks J; Smith JD; Barocas JA; Tookes HE
    Addict Sci Clin Pract; 2024 Mar; 19(1):21. PubMed ID: 38528570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pre-Exposure Prophylaxis Barriers, Facilitators and Unmet Need Among Rural People Who Inject Drugs: A Qualitative Examination of Syringe Service Program Client Perspectives.
    Surratt HL; Yeager HJ; Adu A; González EA; Nelson EO; Walker T
    Front Psychiatry; 2022; 13():905314. PubMed ID: 35706473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Syringe service program-based telemedicine linkage to opioid use disorder treatment: protocol for the STAMINA randomized control trial.
    Watson DP; Swartz JA; Robison-Taylor L; Mackesy-Amiti ME; Erwin K; Gastala N; Jimenez AD; Staton MD; Messmer S
    BMC Public Health; 2021 Mar; 21(1):630. PubMed ID: 33789642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving equity and access to buprenorphine treatment through telemedicine at syringe services programs.
    Lambdin BH; Kan D; Kral AH
    Subst Abuse Treat Prev Policy; 2022 Jul; 17(1):51. PubMed ID: 35841036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of COVID-19 on New York State's Drug User Health Hubs and syringe service programs: a qualitative study.
    Ude M; Behrends CN; Kelly S; Schackman BR; Clear A; Goldberg R; Gelberg K; Kapadia SN
    Harm Reduct J; 2023 Feb; 20(1):12. PubMed ID: 36732773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of Hepatitis C virus among people who inject drugs at a syringe service program during the COVID-19 response: The potential role of telehealth, medications for opioid use disorder and minimal demands on patients.
    Sivakumar A; Madden L; DiDomizio E; Eller A; Villanueva M; Altice FL
    Int J Drug Policy; 2022 Mar; 101():103570. PubMed ID: 34954493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. M
    Martel-Laferrière V; Feaster DJ; Metsch LR; Schackman BR; Loignon C; Nosyk B; Tookes H; Behrends CN; Arruda N; Adigun O; Goyer ME; Kolber MA; Mary JF; Rodriguez AE; Yanez IG; Pan Y; Khemiri R; Gooden L; Sako A; Bruneau J
    Trials; 2022 Apr; 23(1):341. PubMed ID: 35461260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adaptation of the Tele-Harm Reduction intervention to promote initiation and retention in buprenorphine treatment among people who inject drugs: a retrospective cohort study.
    Suarez E; Bartholomew TS; Plesons M; Ciraldo K; Ostrer L; Serota DP; Chueng TA; Frederick M; Onugha J; Tookes HE
    Ann Med; 2023 Dec; 55(1):733-743. PubMed ID: 36856571
    [No Abstract]   [Full Text] [Related]  

  • 14. A qualitative study of service engagement and unmet needs among unstably housed people who inject drugs in Massachusetts.
    Hassan R; Roland KB; Hernandez B; Goldman L; Evans KN; Gaul Z; Agnew-Brune C; Buchacz K; Fukuda HD
    J Subst Abuse Treat; 2022 Jul; 138():108722. PubMed ID: 35067399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Three decades of research in substance use disorder treatment for syringe services program participants: a scoping review of the literature.
    Jakubowski A; Fowler S; Fox AD
    Addict Sci Clin Pract; 2023 Jun; 18(1):40. PubMed ID: 37301953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acceptability of an mHealth App That Provides Harm Reduction Services Among People Who Inject Drugs: Survey Study.
    Shelby T; Zhou X; Barber D; Altice F
    J Med Internet Res; 2021 Jul; 23(7):e25428. PubMed ID: 34259640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Access to HIV, Viral Hepatitis, and Substance Use Disorder Treatment/Overdose Prevention Services: A Qualitative Analysis of Syringe Service Programs (SSPs) Serving Rural PWID.
    Carnes NA; Asher AK; Bohm MK; Bessler PA
    Subst Use Misuse; 2021; 56(13):1933-1940. PubMed ID: 34353216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interest in linkage to PrEP among people who inject drugs accessing syringe services; Miami, Florida.
    Jo Y; Bartholomew TS; Doblecki-Lewis S; Rodriguez A; Forrest DW; Tomita-Barber J; Oves J; Tookes HE
    PLoS One; 2020; 15(4):e0231424. PubMed ID: 32298320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Study protocol for an efficacy trial of the "PrEP for Health" intervention to increase HIV PrEP use among people who inject drugs.
    Bazzi AR; Bordeu M; Baumgartner K; Sproesser DM; Bositis CM; Krakower DS; Mimiaga MJ; Biello KB
    BMC Public Health; 2023 Mar; 23(1):513. PubMed ID: 36932369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Awareness and Correlates of HIV Pre-Exposure Prophylaxis (PrEP) Among HIV-negative People Who Access Syringe Services in Seattle, Washington.
    Corcorran MA; Scott JD; Tinsley J; Wald A; Glick SN
    Subst Use Misuse; 2022; 57(3):337-343. PubMed ID: 34895022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.